TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04953676

Intervention type: PROCEDURE
Group type: OTHER
Intervention: round tunnel technique
Description: Both the femoral tunnel and tibial tunnel were drilled by 8-mm cannulated drill

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flat tunnel technique
Description: Both the femoral tunnel and tibial tunnel were dimension of 5×11-mm rounded-rectangular, which was created by initially drilling a round tunnel with a 5-mm cannulated drill and reshaped by use of a bone rasp and custom-made dilator.
Study: NCT06337721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPEAR (Strategies for Pacific Empowerment and Alcohol Reduction)
Description: This behavioral group intervention will consist of multiple group sessions to reduce AUDs and alcohol-related harms in Pacific Islander young adults. It will infuse culturally resonant narratives, language, and elements into existing evidence-based strategies.
Study: NCT06248827

Intervention type: OTHER
Intervention: Data Collection
Description: Patient data : gender, age, height, weight, daily life (type of job) Diagnostic data : Description of first symptoms/medical history (pain), previous medical history, MRI exams
Study: NCT06022302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet + laxative
Description: The participants will start by consuming one sacket of Movicol powder (13 g macrogol 3350) on the first day. On day 2, the participants will consume two sackets of Movicol powder (26 g macrogol 3350), one with breakfast in the morning and one before sleep in the evening. The participants will continue consuming two sackets per day (one morning, one evening) until the following study visit, day 8 (seven days in total). If the participants have a very loose stomach (recorded as Bristol stool scale ≥6), they will be instructed to reduce Movicol by one sacket/day. In case the participants have not passed a stool on day 2 or in the morning of day 3, the participants will increase the dose to a maximum of three sackets of Movicol powder (39 g macrogol 3350) per day (morning, noon, and evening) and continue this until the following study visit at day 8. If three sackets cause very loose stomach the participants will decrease the number of sackets consumed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet + laxative
Description: The participants will start by consuming one sacket of Movicol powder (13 g macrogol 3350) on the first day. On day 2, the participants will consume two sackets of Movicol powder (26 g macrogol 3350), one with breakfast in the morning and one before sleep in the evening. The participants will continue consuming two sackets per day (one morning, one evening) until the following study visit, day 8 (seven days in total). If the participants have a very loose stomach (recorded as Bristol stool scale ≥6), they will be instructed to reduce Movicol by one sacket/day. In case the participants have not passed a stool on day 2 or in the morning of day 3, the participants will increase the dose to a maximum of three sackets of Movicol powder (39 g macrogol 3350) per day (morning, noon, and evening) and continue this until the following study visit at day 8. If three sackets cause very loose stomach the participants will decrease the number of sackets consumed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet only
Description: This is only a control and participants will not receive Movicol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet only
Description: This is only a control and participants will not receive Movicol.
Study: NCT06278545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FOLFORINOX
Description: One treatment every 14 days :~* Irinotecan 180mg/m² as a 2-hour IV infusion~* Oxaliplatin 85 mg/m² as a 2-hour IV infusion~* Folinic acid 400 mg/m² as 2-hour IV infusion, in Y with oxaliplatin~* 5-FU 2400 mg/m² as a continuous IV infusion over 46 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified FOLFOX
Description: One treatment every 14 days:~* Oxaliplatin 85 mg/m by IV infusion over 2 hours~* Folinic acid: 400 mg/m² or 200 mg/m² if laevorotatory form by IV infusion over 2 hours, in Y with oxaliplatin~* 5FU bolus: 400 mg/m² per 10-minute IV infusion~* 5 FU continuous 2400 mg/m² by IV infusion over 46 hours
Study: NCT06118970

Intervention type: OTHER
Intervention: Neuropsychological tasks and self-report questionnaires
Description: Being a cross-sectional observational study, no intervention will be administered. Subjects will be assessed with neuropsychological tasks and self-report questionnaires.

Intervention type: OTHER
Intervention: Neuropsychological tasks and self-report questionnaires
Description: Being a cross-sectional observational study, no intervention will be administered. Subjects will be assessed with neuropsychological tasks and self-report questionnaires.
Study: NCT05700565

Intervention type: OTHER
Intervention: Extracorporeal photopheresis
Description: ECP consists of the three steps of leukapheresis, photoactivation and reinfusion and has immunomodulatory effects (modulation of dendritic cells, change in cytokine profile, induction of T cell subpopulations). Indications are currently the treatment of Sézary syndrome, Graft-versus-host disease (GvHD), organ transplant rejection and systemic scleroderma.

Intervention type: OTHER
Intervention: Other immunosuppressive or immunomodulatory drugs
Description: Other immunosuppressive or immunomodulatory drugs
Study: NCT06139042

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood drawing
Description: The participants had their blood drawn.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood drawing
Description: The participants had their blood drawn.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood drawing
Description: The participants had their blood drawn.
Study: NCT04805879

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT oral Capsules
Description: Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool donated by a healthy indvidual that was screened to have no mental health issues or chronic or contagious doseases. Each capsule will contain 0.67 ml of pelleted intestinal microbes. Therefore it is considered that the 20 capsules are equivalent to 100 grams of stool

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo Capsules that will look and weigh the same as the FMT oral capsules.
Study: NCT06146894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single obturation technique (Bioceramic Sealer)
Description: Root canal will be obturated using single cone technique using Bioceramic Sealer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral condensation technique (Bioceramic Sealer)
Description: Root canal will be obturated using lateral condensation technique using Bioceramic Sealer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm Vertical condensation technique (Bioceramic Sealer)
Description: Root canal will be obturated using vertical condensation technique using Bioceramic Sealer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral condensation technique (AH Plus Sealer)
Description: Root canal will be obturated using lateral condensation technique using AH plus Sealer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm Vertical condensation technique (AH plus Sealer)
Description: Root canal will be obturated using vertical condensation technique using AH plus Sealer
Study: NCT06330779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma-adapted yoga
Description: Trauma-adapted-yoga (TAY) classes The classes, which span eight weeks with a once-a-week frequency, each last approximately 45-50 minutes. These small group classes are structured in a semi-circle arrangement to create a sense of security and empowerment for the participants. The teaching approach is trauma-sensitive, characterized by its inviting nature, provision of choices when facing challenges (A-B choices), and direction toward tangible physical sensations to enhance interoceptive awareness. Each yoga session follows a structured sequence of activities designed to promote participants' well-being and physiological awareness.~Online TAY classes After eight weeks, adolescents in the yoga group can continue their practice online. Exclusive to previous in-person participants, they'll receive a link for recorded classes and they will have the possibility to contact their health care contact any time.
Study: NCT05960565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: A micro-dose of glucagon is added exactly at the same site as insulin is injected.
Study: NCT06485869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure the improvement in quality of life
Description: Improvment of quality of life is measured by the QLQ-C30 quality of life questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Measure the improvement in quality of life
Description: Improvment of quality of life is measured by the QLQ-C30 quality of life questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure the level of satisfaction of patients and nursing staff
Description: Patient satisfaction is measured using a five-point scale ranging from 1 = strongly disagree to 5 = strongly agree. Higher scores indicate higher levels of satisfaction.

Intervention type: OTHER
Group type: OTHER
Intervention: Measure the level of satisfaction of patients and nursing staff
Description: Patient satisfaction is measured using a five-point scale ranging from 1 = strongly disagree to 5 = strongly agree. Higher scores indicate higher levels of satisfaction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of anxiety and pain
Description: Anxiety and pain is measured by Visual Analogue Scale (VAS). This measurement is complemented by physiological responses to anxiety, measured by heart rate and mean arterial blood pressure (HR and BP)

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of anxiety and pain
Description: Anxiety and pain is measured by Visual Analogue Scale (VAS). This measurement is complemented by physiological responses to anxiety, measured by heart rate and mean arterial blood pressure (HR and BP)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of depressive state
Description: Depressive State is measured by HAD score

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of depressive state
Description: Depressive State is measured by HAD score

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measuring fatigue levels
Description: Fatigue levels is measured by Visual Analogue Scale (VAS).

Intervention type: OTHER
Group type: OTHER
Intervention: measuring fatigue levels
Description: Fatigue levels is measured by Visual Analogue Scale (VAS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of acute nausea and vomiting
Description: acute nausea and vomiting is measured by MASCC Antiemesis Tool (MAT)

Intervention type: OTHER
Group type: OTHER
Intervention: measurement of acute nausea and vomiting
Description: acute nausea and vomiting is measured by MASCC Antiemesis Tool (MAT)
Study: NCT04616066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dates
Description: The effect of date phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raisins
Description: The effect of raisins phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes
Study: NCT05722964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1906
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1906
Description: Intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo，Intravenous injection
Study: NCT05884762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalographic neurofeedback
Description: The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~* Calibration phase at rest.~* Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~  * In the Neurofeedback group, the patient will receive visual feedback of a virtual hand moving on a computer screen in front of him/her, depending on his/her brain activations. He will also receive haptic feedback (vibrations) in the flexor muscles of his wrist.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM electroencephalographic neurofeedback
Description: The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~* Calibration phase at rest.~* Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~  * In the SHAM group, the visual feedback and haptic feedback are randomly generated
Study: NCT05184907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Motivational Enhancement (RME) Intervention Arm
Description: Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing within 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information Only
Description: Participants randomized to the information-only arm will have their CAT-MH, BAM, and PSS screening report results sent to their primary B/N prescriber and will encouraged to set up an appointment with their prescriber within 14 days to discuss the results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
Study: NCT05011396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH94B Nasal Spray
Description: Nasal spray delivered 20 minutes before the public speaking stressor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: Nasal spray delivered 20 minutes before the public speaking stressor
Study: NCT06368726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS or Transcranial Direct Current Stimulation
Description: We use weak currents applied over the child's scalp over 30 minutes twice a week during 100 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone Risperidone according to child's weighs
Study: NCT05726877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation strategy
Description: Titrating positive end-expiratory pressure
Study: NCT06433596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: 3 injections of 10 cc of autologous Platelet Rich Plasma (PRP), weeks 1, 5 and 9

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: 3 injections of 10 cc of autologous Platelet Rich Plasma (PRP), weeks 1, 5 and 9

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shock waves therapy
Description: 6 sessions of focal shock waves, 1 per week
Study: NCT04739020

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Resp-Aer-Meter
Description: Measurement of respiratory aerosols (particle size and concentration) through breathing into the Resp-Aer-Meter for 3-6 Minutes and comparison between groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Resp-Aer-Meter
Description: Measurement of respiratory aerosols (particle size and concentration) through breathing into the Resp-Aer-Meter for 3-6 Minutes and comparison between groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Resp-Aer-Meter
Description: Measurement of respiratory aerosols (particle size and concentration) through breathing into the Resp-Aer-Meter for 3-6 Minutes and comparison between groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Resp-Aer-Meter
Description: Measurement of respiratory aerosols (particle size and concentration) through breathing into the Resp-Aer-Meter for 3-6 Minutes and comparison between groups.
Study: NCT05207228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT
Description: Cognitive behavioral treatment through the web CBT4CBT
Study: NCT04364204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care and BEMPU bracelet
Description: Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. The BEMPU bracelet, also known as the BEMPU Tempwatch, is a silicone band with a thermistor metal cup that emits an audio alarm and flashes an orange light when the body temperature drops below 36.5⁰C, signaling hypothermia and prompting caregiver to provide thermal care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo Mother Care
Description: Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. This is the current standard of care for low birthweight/preterm infants.
Study: NCT04739020

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Comparison of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) between groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Comparison of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) between groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Comparison of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) between groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Comparison of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) between groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations
Description: Comparison between result of aerosol measurement and quantitative and qualitative virus PCR of respiratory secretions that are caught in a filter in which the patient breathes for 10 minutes. Test will be conducted on patients with high aerosol concentrations (\>5000/L).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations
Description: Comparison between result of aerosol measurement and quantitative and qualitative virus PCR of respiratory secretions that are caught in a filter in which the patient breathes for 10 minutes. Test will be conducted on patients with high aerosol concentrations (\>5000/L).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations
Description: Comparison between result of aerosol measurement and quantitative and qualitative virus PCR of respiratory secretions that are caught in a filter in which the patient breathes for 10 minutes. Test will be conducted on patients with high aerosol concentrations (\>5000/L).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations
Description: Comparison between result of aerosol measurement and quantitative and qualitative virus PCR of respiratory secretions that are caught in a filter in which the patient breathes for 10 minutes. Test will be conducted on patients with high aerosol concentrations (\>5000/L).